Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
•
tnbc
How do you administer chemotherapy with Y90 for a triple negative breast cancer patient with BRCA1+ and liver only metastases who is not a candidate for repeat SBRT?
Related Questions
What are your top takeaways in Breast Cancer from ESMO 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ASTRO 2024?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?
In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
What are your top takeaways in Breast Cancer from ASCO 2024?
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
